Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Conditions
Cutaneous Lymphoma | Cutaneous T-cell Lymphoma
What is the purpose of this trial?
The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over low-dose TSEBT alone.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Stanford University
- Dates:
- December 2010
- Last Updated:
- April 24, 2013
- Study HIC#:
- 1008007299
Clinicaltrials.gov ID: NCT01187446
For more information about this trial, contact:
Lynn Wilson, MD
203-737-1202
lynn.wilson@yale.edu
Investigator
Lynn Wilson, MD
Principal Investigator
